Comparison tool

Orforglipron vs Semaglutide side-by-side

Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.

Selected (2/4)

OrforglipronSemaglutide

Share this peptide comparison

Property	Orforglipron	Semaglutide
Category	Weight Loss	Weight Loss
Also known as	LY3502970, OWL833	Ozempic, Wegovy, Rybelsus
FDA approved	Yes	Yes
Clinical status	FDA approved in 2026 for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved	FDA-approved status recorded by the supplied source; it also reports several 2025-2026 indication and formulation updates. Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved
What to expect	Oral weight-loss option, diabetes, convenience	Weight loss, appetite control, blood sugar management
How it works	Orforglipron is described as a small-molecule GLP-1 receptor agonist. The supplied mechanism text connects GLP-1 receptor activation with appetite reduction, slower gastric emptying, and glucose-dependent insulin release. The same evidence emphasizes oral stability as the chemistry-based distinction from peptide GLP-1 agents, not a different receptor target.	According to the supplied description, semaglutide stimulates the GLP-1 receptor. Reported downstream effects include increased insulin secretion when glucose is elevated, decreased glucagon, slower gastric emptying, and hypothalamic appetite signaling. A fatty-acid modification is described as promoting albumin binding and as associated with an approximately 160 hour (about 160 hours) half-life, supporting weekly administration.
Typical dosing	Limited community data available · See research protocols · Oral tablet daily	1-2.4 mg weekly (after titration) · Once weekly
Research dosing	12-45mg once daily · Long-term use expected · Oral tablet daily	0.25mg weekly (starting) · Long-term / chronic use · Subcutaneous injection weekly, or oral (Rybelsus)
Typical duration	Long-term use expected	Long-term / chronic use
Administration	Oral tablet daily	Subcutaneous injection weekly, or oral (Rybelsus)
Timing	- With or without food	Morning, same day each week With or without food
Evidence level	FDA Approved	FDA Approved
Possible side effects	Diarrhea (Reported at 19-26% in the supplied side-effect list.) Nausea (Reported at 13-18% in the supplied side-effect list.) Vomiting (Listed among reported gastrointestinal events.) +3 more Gastrointestinal events (Source characterizes GI events as generally mild to moderate.) Pulse increase (Listed as a reported effect without a quantitative value.) Investigational/not-yet-approved caution (Included in the side-effect list, but it conflicts with FDA-approved statements elsewhere in the input.)	Nausea (Common and usually transient; the source says reports vary with dose, duration, and individual health factors.) Vomiting Diarrhea +10 more Constipation Abdominal pain Headache Fatigue Injection site reactions Hypoglycemia (Source associates this report with insulin/sulfonylureas.) Gallbladder problems Pancreatitis Acute kidney injury Thyroid C-cell tumors (Boxed warning; the source lists a contraindication with MTC/MEN 2.)
Research summary	The source summarizes a late-stage clinical program. It reports ATTAIN-1 as a 72-week obesity trial in which three dose groups outperformed placebo for weight loss, with full results said to appear in the New England Journal of Medicine. ATTAIN-2 is described in adults with obesity and type 2 diabetes, with weight loss and changes in waist circumference, blood pressure, non-HDL cholesterol, and triglycerides. For diabetes, ACHIEVE-1 is characterized as a Phase 3 success for an oral small-molecule GLP-1 agent, and ACHIEVE-3 is reported as a head-to-head comparison where orforglipron exceeded oral semaglutide on A1C and weight. The same source frames the main advance as oral delivery rather than a new GLP-1 mechanism.	The source characterizes the clinical literature as extensive. It reports that the SUSTAIN program established blood-sugar control in type 2 diabetes and that SUSTAIN 6 reduced cardiovascular events. For STEP 1, published in the New England Journal of Medicine in 2021, the source describes nearly 2,000 adults without diabetes in a randomized trial: at a 68 week endpoint, semaglutide 2.4 mg had 14.9 % mean weight loss versus 2.4 % with placebo, and most participants lost at least 5 %. It characterizes this as large randomized, placebo-controlled research rather than pilot data. Gastrointestinal effects, including nausea, vomiting, and constipation, were reported as most prominent during escalation; the source also reports an oral weight-management version as approved.
References	The Lancet Eli Lilly +3 more Eli Lilly Investor Eli Lilly MDPI	Source Source +2 more Source Source
Full profile	View Details	View Details

Save this comparison

Keep this research set handy with a free PeptiGuide account.

Save this comparison - free account

Track your peptide journey

Turn research into a private protocol log when you are ready.

Track your peptide journey

Educational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.

Property

Orforglipron

Semaglutide

Category

Weight Loss

Also known as

LY3502970, OWL833

Ozempic, Wegovy, Rybelsus

FDA approved

Yes

Clinical status

FDA approved in 2026 for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity.

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

FDA-approved status recorded by the supplied source; it also reports several 2025-2026 indication and formulation updates.

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

What to expect

Oral weight-loss option, diabetes, convenience

Weight loss, appetite control, blood sugar management

How it works

Orforglipron is described as a small-molecule GLP-1 receptor agonist. The supplied mechanism text connects GLP-1 receptor activation with appetite reduction, slower gastric emptying, and glucose-dependent insulin release. The same evidence emphasizes oral stability as the chemistry-based distinction from peptide GLP-1 agents, not a different receptor target.

According to the supplied description, semaglutide stimulates the GLP-1 receptor. Reported downstream effects include increased insulin secretion when glucose is elevated, decreased glucagon, slower gastric emptying, and hypothalamic appetite signaling. A fatty-acid modification is described as promoting albumin binding and as associated with an approximately 160 hour (about 160 hours) half-life, supporting weekly administration.

Typical dosing

Limited community data available · See research protocols · Oral tablet daily

1-2.4 mg weekly (after titration) · Once weekly

Research dosing

12-45mg once daily · Long-term use expected · Oral tablet daily

0.25mg weekly (starting) · Long-term / chronic use · Subcutaneous injection weekly, or oral (Rybelsus)

Typical duration

Long-term use expected

Long-term / chronic use

Administration

Oral tablet daily

Subcutaneous injection weekly, or oral (Rybelsus)

Timing

With or without food

Morning, same day each week

With or without food

Evidence level

FDA Approved

Possible side effects

Diarrhea (Reported at 19-26% in the supplied side-effect list.)
Nausea (Reported at 13-18% in the supplied side-effect list.)
Vomiting (Listed among reported gastrointestinal events.)

+3 more

Gastrointestinal events (Source characterizes GI events as generally mild to moderate.)
Pulse increase (Listed as a reported effect without a quantitative value.)
Investigational/not-yet-approved caution (Included in the side-effect list, but it conflicts with FDA-approved statements elsewhere in the input.)

Nausea (Common and usually transient; the source says reports vary with dose, duration, and individual health factors.)
Vomiting
Diarrhea

+10 more

Constipation
Abdominal pain
Headache
Fatigue
Injection site reactions
Hypoglycemia (Source associates this report with insulin/sulfonylureas.)
Gallbladder problems
Pancreatitis
Acute kidney injury
Thyroid C-cell tumors (Boxed warning; the source lists a contraindication with MTC/MEN 2.)

Research summary

The source summarizes a late-stage clinical program. It reports ATTAIN-1 as a 72-week obesity trial in which three dose groups outperformed placebo for weight loss, with full results said to appear in the New England Journal of Medicine. ATTAIN-2 is described in adults with obesity and type 2 diabetes, with weight loss and changes in waist circumference, blood pressure, non-HDL cholesterol, and triglycerides. For diabetes, ACHIEVE-1 is characterized as a Phase 3 success for an oral small-molecule GLP-1 agent, and ACHIEVE-3 is reported as a head-to-head comparison where orforglipron exceeded oral semaglutide on A1C and weight. The same source frames the main advance as oral delivery rather than a new GLP-1 mechanism.

The source characterizes the clinical literature as extensive. It reports that the SUSTAIN program established blood-sugar control in type 2 diabetes and that SUSTAIN 6 reduced cardiovascular events. For STEP 1, published in the New England Journal of Medicine in 2021, the source describes nearly 2,000 adults without diabetes in a randomized trial: at a 68 week endpoint, semaglutide 2.4 mg had 14.9 % mean weight loss versus 2.4 % with placebo, and most participants lost at least 5 %. It characterizes this as large randomized, placebo-controlled research rather than pilot data. Gastrointestinal effects, including nausea, vomiting, and constipation, were reported as most prominent during escalation; the source also reports an oral weight-management version as approved.

References

The Lancet Eli Lilly

+3 more

Eli Lilly Investor Eli Lilly MDPI

Source Source

+2 more

Source Source

Full profile

View Details